Please assess the completion status of the following clinical trial:

Trial Title: Effects of Psilocybin in Concussion Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of post-traumatic headache~* Typical pattern of headache attacks with approximately two attacks or more weekly~* Attacks are managed by means involving no more than twice weekly triptan use~Exclusion Criteria:~* Axis I psychotic disorder (e.g. schizophrenia, bipolar I, depression with psychosis)~* Axis I psychotic disorder in first degree relative~* Unstable medical condition, severe renal, cardiac or hepatic disease, pacemaker, or serious central nervous system pathology~* Pregnant, breastfeeding, lack of adequate birth control~* History of intolerance to psilocybin, LSD, or related compounds~* Drug or alcohol abuse within the past 3 months (excluding tobacco)~* Urine toxicology positive to drugs of abuse~* Use of vasoconstrictive medications (i.e. sumatriptan, pseudoephedrine, midodrine) within 5 half-lives of test days~* Use of serotonergic antiemetics (i.e. ondansetron) in the past 2 weeks~* Use of antidepressant medication (i.e. TCA, MAOI, SSRI) in the past 6 weeks~* Use of steroids or certain other immunomodulatory agents (i.e. azathioprine) in the past 2 weeks

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo/Low Dose Psilocybin (Type: EXPERIMENTAL): Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
- Placebo/High Dose Psilocybin (Type: EXPERIMENTAL): Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
- Low Dose Psilocybin/Placebo (Type: EXPERIMENTAL): Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
- High Dose Psilocybin/Placebo (Type: EXPERIMENTAL): Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
- High Dose Psilocybin/Low Dose Psilocybin (Type: EXPERIMENTAL): Subjects in this arm receive high dose psilocybin in the first session and low dose psilocybin in the second session.
- Low Dose Psilocybin/High Dose Psilocybin (Type: EXPERIMENTAL): Subjects in this arm receive low dose psilocybin in the first session and high dose psilocybin in the second session.

Based on this trial design, predict the completion outcome and termination type (if applicable).